On the one hand, the efficacy of MSC-exos alone in the treatment of liver fibrosis was assessed in terms of the pathological histological changes in the liver (Masson-stained area and Sirius red-stained area), the progression of hepatic fibrosis (Ishak score, liver index, and α-SMA), and the liver function (ALT, AST, ALP, and Hyp). The gene discussed is ACTA1; the disease is Hepatic fibrosis.